177 related articles for article (PubMed ID: 32633067)
1. Comparison between coagulation factor VIII quantified with one-stage activity assay and with mass spectrometry in haemophilia A patients: Proof of principle.
Donners AAMT; van Maarseveen EM; Weetink YRJ; El Amrani M; Fischer K; Rademaker CMA; Egberts TCG; Huisman A; Musson REA
Int J Lab Hematol; 2020 Dec; 42(6):819-826. PubMed ID: 32633067
[TBL] [Abstract][Full Text] [Related]
2. Quantification of coagulation factor VIII in human plasma with liquid chromatography tandem mass spectrometry using a selective sample purification with camelid nanobodies.
El Amrani M; Donners AAM; Graat G; Lentjes EG; Huisman A; Musson REA; van Maarseveen EM
J Pharm Biomed Anal; 2019 Oct; 175():112781. PubMed ID: 31398627
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of different factor VIII replacement products using a factor VIII one-stage clotting assay on cobas t 511/711 analysers.
Ketteler C; Hoffmann I; Davidson S; Tiede A; Richter N
Haemophilia; 2021 Nov; 27(6):e704-e712. PubMed ID: 34590394
[TBL] [Abstract][Full Text] [Related]
4. Thrombin generation assay using factor IXa as a trigger to quantify accurately factor VIII levels in haemophilia A.
Ninivaggi M; Dargaud Y; van Oerle R; de Laat B; Hemker HC; Lindhout T
J Thromb Haemost; 2011 Aug; 9(8):1549-55. PubMed ID: 21605333
[TBL] [Abstract][Full Text] [Related]
5. Clot waveform analysis using CS-2000i™ distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A.
Matsumoto T; Nogami K; Tabuchi Y; Yada K; Ogiwara K; Kurono H; Arai N; Shima M
Haemophilia; 2017 Sep; 23(5):e427-e435. PubMed ID: 28750470
[TBL] [Abstract][Full Text] [Related]
6. Normalization of factor VIII levels in a patient with mild haemophilia A during a 35-year period.
Mainwaring CJ; Evans J; Chana J; Lewis H
Haemophilia; 2006 Nov; 12(6):668-71. PubMed ID: 17083519
[TBL] [Abstract][Full Text] [Related]
7. Analytical variation in factor VIII one-stage and chromogenic assays: Experiences from the ECAT external quality assessment programme.
van Moort I; Meijer P; Priem-Visser D; van Gammeren AJ; Péquériaux NCV; Leebeek FWG; Cnossen MH; de Maat MPM
Haemophilia; 2019 Jan; 25(1):162-169. PubMed ID: 30488994
[TBL] [Abstract][Full Text] [Related]
8. Impact of variation in reagent combinations for one-stage clotting assay on assay discrepancy in nonsevere haemophilia A.
Suzuki A; Suzuki N; Kanematsu T; Okamoto S; Tamura S; Kikuchi R; Katsumi A; Kiyoi H; Kojima T; Matsushita T
Int J Lab Hematol; 2021 Feb; 43(1):131-138. PubMed ID: 32915508
[TBL] [Abstract][Full Text] [Related]
9. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
[TBL] [Abstract][Full Text] [Related]
10. Agreement between one stage and chromogenic assays in samples from patients receiving recombinant porcine FVIII (Obizur, Susoctocog-alfa).
Guy S; Bowyer AE; Shepherd MF; Maclean RM; Kitchen S
Int J Lab Hematol; 2024 Feb; 46(1):135-140. PubMed ID: 37799011
[TBL] [Abstract][Full Text] [Related]
11. Multicenter performance evaluation and reference range determination of a new one-stage factor VIII assay.
Lowe AE; Jones R; Kitchen S; Geisen U; Rozsnyai G; Jilma P; Quehenberger P
J Clin Lab Anal; 2022 Apr; 36(4):e24294. PubMed ID: 35274775
[TBL] [Abstract][Full Text] [Related]
12. One-stage vs. chromogenic assays in haemophilia A.
Potgieter JJ; Damgaard M; Hillarp A
Eur J Haematol; 2015 Feb; 94 Suppl 77():38-44. PubMed ID: 25560793
[TBL] [Abstract][Full Text] [Related]
13. The use of the new ReFacto AF Laboratory Standard allows reliable measurement of FVIII:C levels in ReFacto AF mock plasma samples by a one-stage clotting assay.
Pouplard C; Caron C; Aillaud MF; Ternisien C; Desconclois C; Dubanchet A; Sobas F
Haemophilia; 2011 Sep; 17(5):e958-62. PubMed ID: 21457408
[TBL] [Abstract][Full Text] [Related]
14. Accurate measurement of extended half-life and unmodified factor VIII low levels with one-stage FVIII assays is dependent on the matrix of calibration curves.
Van den Bossche D; Toelen J; Schoeters J; Van Horenbeeck I; Vanlinthout I; Debasse M; Peerlinck K; Jacquemin M
Haemophilia; 2019 Jan; 25(1):e19-e26. PubMed ID: 30589148
[TBL] [Abstract][Full Text] [Related]
15. Factor VIII assay mimicking in vivo coagulation conditions.
Kusch M; Grundmann C; Keitel S; König H
Haemophilia; 2014 Mar; 20(2):e164-70. PubMed ID: 24286249
[TBL] [Abstract][Full Text] [Related]
16. A ROTEM method using APTT reagent and tissue factor as the clotting activators may better define bleeding heterogeneity in moderate or severe haemophilia A (part I: Study in plasma samples).
He S; Eelde A; Petrini P; Wallen H; Gabrielsson L; Svensson J; Blombäck M; Holmström M
Thromb Res; 2018 Nov; 171():7-13. PubMed ID: 30216822
[TBL] [Abstract][Full Text] [Related]
17. Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII).
Santoro C; Iorio A; Ferrante F; Pallotta A; Pignoloni P; Biondo F; Agnelli G; Mazzucconi MG
Haemophilia; 2009 May; 15(3):779-87. PubMed ID: 19298379
[TBL] [Abstract][Full Text] [Related]
18. Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy.
Gilmore R; Harmon S; Gannon C; Byrne M; O'Donnell JS; Jenkins PV
Haemophilia; 2010 Jul; 16(4):671-4. PubMed ID: 20148980
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of an automated chromogenic assay for Factor VIII clotting activity measurement in patients affected by haemophilia A.
Novembrino C; Boscolo Anzoletti M; Mancuso ME; Shinohara S; Peyvandi F
Haemophilia; 2019 May; 25(3):521-526. PubMed ID: 31044485
[TBL] [Abstract][Full Text] [Related]
20. Regression Analysis to Estimate the Factor VIII Activity of Patients with Hemophilia A Without Inhibitor who Received Emicizumab Therapy.
Hatayama Y; Motokura T; Hosoda Y; Suzuki S; Namba H; Kato K; Kojima N; Horie T; Iwamoto T; Yamashita N; Ichikawa H; Fukuda T
Clin Appl Thromb Hemost; 2022; 28():10760296221082992. PubMed ID: 35225012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
